| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
69,110,000 |
| Market
Cap: |
2.51(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$19.97 - $38.81 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agios Pharmaceuticals is a biopharmaceutical company focused on improving patients' lives in the field of cellular metabolism and adjacent areas of biology, with the goal of creating molecule medicines for genetically defined diseases (GDD). The lead product in its GDD, portfolio, PYRUKYND® (mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the potential treatment of hemolytic anemias. Co. is evaluating PYRUKYND® for the treatment of a- and B-thalassemia and sickle cell disease (SCD). Co. is also developing AG-946, a PK activator, for the potential treatment of hemolytic anemias and other indications, including SCD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
27,030 |
218,053 |
292,572 |
410,176 |
| Total Sell Value |
$835,799 |
$6,694,407 |
$8,693,794 |
$11,787,151 |
| Total People Sold |
7 |
9 |
9 |
9 |
| Total Sell Transactions |
10 |
28 |
39 |
48 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Maraganore John |
Director |
– • – |
2020-02-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,315 |
28,294 |
|
- |
|
| Bowden Christopher |
Chief Medical Officer |
• – – |
2020-02-13 |
4 |
AS |
$50.16 |
$356,112 |
D/D |
(7,100) |
1,650 |
|
2% |
|
| Bowden Christopher |
Chief Medical Officer |
• – – |
2020-02-13 |
4 |
OE |
$35.16 |
$249,636 |
D/D |
7,100 |
8,750 |
|
- |
|
| Bowden Christopher |
Chief Medical Officer |
• – – |
2020-02-11 |
4 |
AS |
$50.02 |
$31,063 |
D/D |
(621) |
1,650 |
|
-1% |
|
| Bowden Christopher |
Chief Medical Officer |
• – – |
2020-02-11 |
4 |
OE |
$35.16 |
$21,834 |
D/D |
621 |
2,271 |
|
- |
|
| Bowden Christopher |
Chief Medical Officer |
• – – |
2020-02-05 |
4 |
OE |
$35.16 |
$1,246,317 |
D/D |
35,447 |
37,097 |
|
- |
|
| Bowden Christopher |
Chief Medical Officer |
• – – |
2020-02-04 |
4 |
AS |
$50.03 |
$2,485,989 |
D/D |
(49,638) |
1,650 |
|
-3% |
|
| Bowden Christopher |
Chief Medical Officer |
• – – |
2020-02-04 |
4 |
OE |
$35.16 |
$299,774 |
D/D |
8,526 |
15,841 |
|
- |
|
| Alenson Carman |
Principal Accounting Officer |
• – – |
2019-12-26 |
4 |
AS |
$50.09 |
$147,766 |
D/D |
(2,950) |
184 |
|
- |
|
| Celgene Alpine Investment Co., Llc |
10% Owner |
– – • |
2019-11-12 |
4 |
B |
$31.00 |
$12,499,975 |
D/D |
403,225 |
1,777,824 |
2.45 |
- |
|
| Maraganore John |
Director |
– • – |
2019-06-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,000 |
32,609 |
|
- |
|
| Biller Scott |
Chief Scientific Officer |
• – – |
2019-06-11 |
4 |
OE |
$2.34 |
$16,872 |
D/D |
7,218 |
33,729 |
|
- |
|
| Scadden David |
Director |
– • – |
2019-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,400 |
1,971 |
|
- |
|
| Clark Ian T |
Director |
– • – |
2019-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,400 |
1,400 |
|
- |
|
| Foster-Cheek Kaye I |
Director |
– • – |
2019-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,400 |
3,600 |
|
- |
|
| Ho Maykin |
Director |
– • – |
2019-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,400 |
1,400 |
|
- |
|
| Maraganore John |
Director |
– • – |
2019-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,400 |
37,609 |
|
- |
|
| Fouse Jacqualyn A |
Chief Executive Officer |
• • – |
2019-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,400 |
1,400 |
|
- |
|
| Clancy Paul J |
Director |
– • – |
2019-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,400 |
1,400 |
|
- |
|
| Biller Scott |
Chief Scientific Officer |
• – – |
2019-04-05 |
4 |
AS |
$67.61 |
$203,135 |
D/D |
(3,000) |
26,511 |
|
- |
|
| Biller Scott |
Chief Scientific Officer |
• – – |
2019-04-05 |
4 |
OE |
$39.76 |
$119,280 |
D/D |
3,000 |
29,511 |
|
- |
|
| Bowden Christopher |
Chief Medical Officer |
• – – |
2019-04-01 |
4 |
AS |
$66.03 |
$665,747 |
D/D |
(10,000) |
7,238 |
|
- |
|
| Bowden Christopher |
Chief Medical Officer |
• – – |
2019-04-01 |
4 |
OE |
$35.16 |
$351,600 |
D/D |
10,000 |
17,238 |
|
- |
|
| Bowden Christopher |
Chief Medical Officer |
• – – |
2019-03-15 |
4 |
AS |
$64.09 |
$641,615 |
D/D |
(10,000) |
7,238 |
|
- |
|
| Bowden Christopher |
Chief Medical Officer |
• – – |
2019-03-15 |
4 |
OE |
$35.16 |
$351,600 |
D/D |
10,000 |
17,238 |
|
- |
|
822 Records found
|
|
Page 12 of 33 |
|
|
1.20 (3.2%) 
